Evotec SE (ETR:EVT – Get Free Report)’s share price traded up 0.2% on Tuesday . The stock traded as high as €5.20 and last traded at €5.15. 304,965 shares changed hands during trading, a decline of 78% from the average session volume of 1,360,000 shares. The stock had previously closed at €5.14.
Evotec Price Performance
The company has a current ratio of 1.68, a quick ratio of 2.97 and a debt-to-equity ratio of 55.38. The company has a market capitalization of $907.69 million, a P/E ratio of -5.29, a P/E/G ratio of 0.98 and a beta of 1.31. The business’s fifty day moving average price is €4.97 and its 200-day moving average price is €5.28.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.
Read More
- Five stocks we like better than Evotec
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
